| Members |
targetComponentId |
| T3: Lung tumor of any size that directly invades any of the following: chest wall (including superior sulcus tumors); diaphragm; mediastinal pleura; parietal pericardium |
American Joint Committee on Cancer cT3 (qualifier value) |
| T3: Pancreatic tumor extends directly to any of the following: duodenum; bile duct; peripancreatic tissues |
American Joint Committee on Cancer cT3 (qualifier value) |
| T3: Pleural tumor invades any of the following: ipsilateral chest wall muscle, ribs, or media-stinal organs or tissues |
American Joint Committee on Cancer cT3 (qualifier value) |
| T3: Prostate tumor extends through the prostatic capsule |
American Joint Committee on Cancer cT3 (qualifier value) |
| T3: Renal pelvis tumor invades beyond muscularis peripelvic fat or the renal parenchyma |
American Joint Committee on Cancer cT3 (qualifier value) |
| T3: Renal tumor extends into major veins or invades the adrenal gland or perinephric tissues but not beyond Gerota's fascia |
American Joint Committee on Cancer cT3 (qualifier value) |
| T3: Stomach tumor penetrates serosa without invasion of adjacent structures |
American Joint Committee on Cancer cT3 (qualifier value) |
| T3: Testicular tumor invades spermatic cord with or without vascular/lymphatic invasion |
American Joint Committee on Cancer cT3 (qualifier value) |
| T3: Thyroid tumor > 4 cm, limited to thyroid |
American Joint Committee on Cancer cT3 (qualifier value) |
| T3: Ureteral tumor invades beyond muscularis into periureteric fat |
American Joint Committee on Cancer cT3 (qualifier value) |
| T3: Urinary bladder tumor invades perivesical tissue |
American Joint Committee on Cancer cT3 (qualifier value) |
| T3a (IIIA): Fallopian tube/ovarian tumor with microscopic peritoneal metastasis beyond pelvis |
American Joint Committee on Cancer cT3a (qualifier value) |
| T3a (IIIA): Tumor of uterine cervix involves lower third of vagina, but not pelvic wall |
American Joint Committee on Cancer cT3a (qualifier value) |
| T3a: Bladder tumor invades perivesical tissue microscopically |
American Joint Committee on Cancer cT3a (qualifier value) |
| T3a: Prostate tumor with extracapsular extension (unilateral or bilateral) |
American Joint Committee on Cancer cT3a (qualifier value) |
| T3a: Renal tumor invades the adrenal gland or perinephric tissues but not beyond Gerota's fascia |
American Joint Committee on Cancer cT3a (qualifier value) |
| T3b (IIIB): Endometrial tumor with vaginal involvement (direct extension or metastasis) |
cT3b |
| T3b (IIIB): Fallopian tube/ovarian tumor with macroscopic peritoneal metastasis beyond pelvis < 2 cm in greatest dimension |
cT3b |
| T3b (IIIB): Tumor of uterine cervix extends to pelvic wall and/or causes hydronephrosis or nonfunctioning kidney |
cT3b |
| T3b: Bladder tumor invades perivesical tissue macroscopically (extravesicular mass) |
cT3b |
| T3b: Prostate tumor invades the seminal vesicle(s) |
cT3b |
| T3b: Renal tumor grossly extends into the renal vein(s) or vena cava below the diaphragm |
cT3b |
| T3c (IIIC): Fallopian tube/ovarian tumor with peritoneal metastasis beyond pelvis > 2 cm in greatest dimension and/or regional lymph node metastasis |
American Joint Committee on Cancer cT3c (qualifier value) |
| T3c: Renal tumor grossly extends into the vena cava above the diaphragm |
American Joint Committee on Cancer cT3c (qualifier value) |
| T4 (IVA): Endometrial tumor invades bladder mucosa and/or bowel mucosa |
cT4 |
| T4 (IVA): Tumor of uterine cervix/vagina invades mucosa of bladder or rectum and/or extends beyond true pelvis |
cT4 |
| T4 category |
cT4 |
| T4: Aerodigestive tract tumor invades adjacent structures (pterygoid muscles, mandible, hard palate, deep muscle of tongue, larynx) |
cT4 |
| T4: Aerodigestive tract tumor invades adjacent structures (thyroid/cricoid cartilage, carotid artery, soft tissues of neck, prevertebral fascia/muscles, thyroid and/or esophagus) |
cT4 |
| T4: Aerodigestive tract tumor invades orbital contents beyond the floor or medial wall including apex and/or any of the following: cribriform plate, base of skull, nasopharynx, sphenoid sinus, frontal sinus |
cT4 |
| T4: Aerodigestive tract tumor with intracranial extension and/or involvement of cranial nerves, infratemporal fossa, hypopharynx or orbit |
cT4 |
| T4: Aerodigestive tract tumor with intracranial extension, orbital extension including apex, involving sphenoid and/or frontal sinus and/or skin of nose |
cT4 |
| T4: Aerodigestive tumor invades base of skull, seventh nerve, and/or exceeds 6 cm in greatest dimension |
cT4 |
| T4: Ampulla tumor invades >2 cm into pancreas and/or into other adjacent organs |
cT4 |
| T4: Breast tumor of any size with direct extension to chest wall or skin |
cT4 |
| T4: Lip: Tumor invades adjacent structures (cortical bone, inferior alveolar nerve, floor of mouth, skin of face) |
cT4 |
| T4: Lung tumor of any size that invades any of the following: mediastinum; heart; great vessels; trachea; esophagus; vertebral body; carina |
cT4 |
| T4: Lung tumor of any size with a malignant pleural effusion |
cT4 |
| T4: Lung tumor of any size with separate tumor nodule(s) in same lobe |
cT4 |
| T4: Oral Cavity: Tumor invades adjacent structures (cortical bone, deep (extrinsic) muscle of tongue, maxillary sinus, skin) |
cT4 |
| T4: Pancreas tumor extends directly to any of the following: stomach; spleen; colon; adjacent large vessels |
cT4 |
| T4: Pleural tumor directly extends to any of the following: contralateral pleura, contralateral lung, peritoneum, intra-abdominal organs, cervical tissues |
cT4 |
| T4: Renal pelvis/ureter tumor invades adjacent organs, or through the kidney into the perinephric fat |
cT4 |
| T4: Renal tumor invades beyond Gerota's fascia |
cT4 |
| T4: Testicular tumor invades scrotum with or without vascular/lymphatic invasion |
cT4 |
| T4: Thyroid tumor of any size extending beyond the thyroid capsule |
cT4 |
| T4: Tumor directly invades adjacent structures |
cT4 |
| T4: Tumor invades through cricoid or thyroid cartilage and/or extends into other tissues beyond the larynx (trachea, soft tissues of neck, thyroid, esophagus) |
cT4 |
| T4: Tumor invades through thyroid cartilage and/or extends to other tissues beyond the larynx (trachea, soft tissues of neck, pharynx) |
cT4 |
| T4: Tumor invades through thyroid cartilage, and/or extends into soft tissues of the neck, thyroid, and/or esophagus |
cT4 |
| T4: Urinary bladder tumor invades any of the following: prostate, uterus, vagina, pelvic wall abdominal wall |
cT4 |
| T4a: Bladder tumor invades prostate or uterus or vagina |
American Joint Committee on Cancer cT4a (qualifier value) |
| T4a: Breast tumor with extension to chest wall |
American Joint Committee on Cancer cT4a (qualifier value) |
| T4a: Colon/rectum tumor directly invades other organs or structures |
American Joint Committee on Cancer cT4a (qualifier value) |
| T4b: Bladder tumor invades pelvic wall or abdominal wall |
cT4b |
| T4b: Colon/rectum tumor penetrates the visceral peritoneum |
cT4b |
| T4b: Edema (including peau d'orange) or ulceration of the skin of the breast or satellite skin nodules confined to the same breast |
cT4b |
| T4c: Breast tumor, both T4a and T4b |
American Joint Committee on Cancer cT4c (qualifier value) |
| T4d: Inflammatory carcinoma (breast) |
American Joint Committee on Cancer cT4d (qualifier value) |
| T4d: Inflammatory carcinoma of breast with involvement of skin and chest wall by carcinoma |
American Joint Committee on Cancer cT4d (qualifier value) |
| TNM tumour staging |
American Joint Committee on Cancer allowable value |
| TNM tumour staging |
American Joint Committee on Cancer allowable value |
| TX category |
American Joint Committee on Cancer cTX (qualifier value) |
| Ta: Noninvasive papillary carcinoma (urinary tract) |
American Joint Committee on Cancer cTa (qualifier value) |
| Tacaribe virus complex |
Mammarenavirus |
| Tacrolimus 0.03% ointment |
Product containing precisely tacrolimus 300 microgram/1 gram conventional release cutaneous ointment (clinical drug) |
| Tacrolimus 0.1% ointment |
Product containing precisely tacrolimus 1 milligram/1 gram conventional release cutaneous ointment (clinical drug) |
| Tacrolimus 1mg modified-release tablet |
Tacrolimus only product in oral dose form |
| Tacrolimus 1mg prolonged-release oral tablet |
Tacrolimus only product in oral dose form |
| Tacrolimus 4mg modified-release tablet |
Tacrolimus only product in oral dose form |
| Tacrolimus 4mg prolonged-release oral tablet |
Tacrolimus only product in oral dose form |
| Tacrolimus 5mg/1mL infusion concentrate |
Product containing precisely tacrolimus 5 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| Tacrolimus 5mg/mL infusion concentrate 1mL ampule |
Product containing precisely tacrolimus 5 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| Tacrolimus 5mg/mL injection |
Product containing precisely tacrolimus 5 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| Tacrolimus 5mg/mL injection solution 1mL vial |
Product containing precisely tacrolimus 5 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| Tacrolimus 750microgram modified-release tablet |
Tacrolimus only product in oral dose form |
| Tacrolimus 750microgram prolonged-release orale tablet |
Tacrolimus only product in oral dose form |
| Tacrolimus monohydrate 0.03% ointment |
Product containing precisely tacrolimus 300 microgram/1 gram conventional release cutaneous ointment (clinical drug) |
| Tacrolimus monohydrate 0.1% ointment |
Product containing precisely tacrolimus 1 milligram/1 gram conventional release cutaneous ointment (clinical drug) |
| Taenia multiceps |
Taenia multiceps |
| Take-down of arteriovenous shunt |
Removal of arteriovenous shunt device |
| Taking swab for specific organism |
Taking swab for microbiology |
| Taking swab from body site |
Taking of swab |
| Tamoxifen 10mg tablet |
Product containing precisely tamoxifen (as tamoxifen citrate) 10 milligram/1 each conventional release oral tablet (clinical drug) |
| Tamoxifen 20mg tablet |
Product containing precisely tamoxifen (as tamoxifen citrate) 20 milligram/1 each conventional release oral tablet (clinical drug) |
| Tamoxifen citrate 10mg |
Product containing precisely tamoxifen (as tamoxifen citrate) 10 milligram/1 each conventional release oral tablet (clinical drug) |
| Tamoxifen citrate 10mg tablet |
Product containing precisely tamoxifen (as tamoxifen citrate) 10 milligram/1 each conventional release oral tablet (clinical drug) |
| Tamsulosin hydrochloride 400micrograms m/r tablet |
Tamsulosin only product in oral dose form |
| Tamsulosin hydrochloride 400micrograms prolonged-release oral tablet |
Tamsulosin only product in oral dose form |
| Tannin |
Tannic acid |
| Tapeworm larvae |
Class Cestoda larva |
| Tardive dyskinesia |
Tardive dyskinesia |
| Teacher of the mentally handicapped |
Intellectual disability teacher |
| Technetium Tc^99c^ medronate |
Technetium (99m-Tc) medronate (substance) |
| Technetium[99mTc] albumin colloid (nanosized) injection |
Product containing technetium (99m-Tc) aggregated albumin in parenteral dose form (medicinal product form) |
| Technetium[99mTc] albumin colloid (nanosized) injection |
Product containing technetium (99m-Tc) aggregated albumin in parenteral dose form (medicinal product form) |
| Technetium[99mTc] albumin millimicrospheres injection |
Product containing technetium (99m-Tc) aggregated albumin in parenteral dose form (medicinal product form) |
| Technetium[99mTc] albumin millimicrospheres injection |
Product containing technetium (99m-Tc) aggregated albumin in parenteral dose form (medicinal product form) |
| Teeth covered in plaque |
Dental plaque on teeth |
| Teichococcus ludipueritiae |
Roseomonas ludipueritiae (organism) |
| Telephoned report |
Telephoned report (record artifact) |
FHIR